Subsequently, we determined the prognostic impact of MYLK2 on PRAD patients based on machine learning, and the results showed that MYLK2 was more important than CPH in RSF, and its importance first increased and then decreased with time, which we hypothesised might be related to late gene mutations in PRAD patients. This evidence concerns the gene MYLK2 and prostate adenocarcinoma.